Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety and Tolerability of CKD-388 in Healthy Subjects
NCT04676893Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Feb 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-388 in Chronic Hepatitis B (CHB) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Concentration-time Curve to the Last Measurable Concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Status: unknown.
02
Drugs
CKD-388
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04676893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676893.